Literature DB >> 26855504

Chronic Graft Versus Host Disease in Acute Leukemia Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant: Analysis of Risk Factors, Pattern and Long Term Outcome.

Sachin Punatar1, Alok Gupta1, Jayant Gawande1, Bhausaheb Bagal1, Libin Mathew1, Sadhana Kannan2, Navin Khattry1.   

Abstract

Chronic graft versus host disease (cGVHD) is a common late complication of allogenic hematopoietic stem cell transplant (HSCT). We analyzed risk factors, pattern and long term transplant outcomes of cGVHD at a tertiary cancer centre. Seventy-seven consecutive patients who underwent HSCT for acute leukemia were included. Forty (52 %) patients developed cGVHD; 24 (60 %) extensive stage while 16 (40 %) limited stage. Oral cavity was the commonest site of involvement (25 patients) followed by liver, skin and lung. We found that female donor to male recipient transplant and diagnosis of acute lymphoblastic leukemia (ALL) were the only factors associated with increased risk of cGVHD. The incidence of leukemia relapse was 18 % in patients who developed cGVHD compared to 51 % in those who did not (P = 0.002). Four year overall survival and relapse free survival (RFS) were 62 and 46 % in patients who developed cGVHD compared to 29 % (P < 0.001) and 29 % (P < 0.001) in patients who did not develop cGVHD, respectively. We conclude that cGVHD is more common in male patients with female donors and in patients transplanted for ALL. Oral cavity is the commonest site of cGVHD in our patients and transplant related survival outcomes are superior in patients who develop cGVHD.

Entities:  

Keywords:  Acute leukemia; Allogeneic stem cell transplantation; Chronic graft-versus-host disease; Outcome; Risk factors

Year:  2015        PMID: 26855504      PMCID: PMC4733673          DOI: 10.1007/s12288-015-0506-5

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN: 0971-4502            Impact factor:   0.900


  14 in total

1.  Chronic graft-versus-host disease after allogeneic peripheral blood progenitor cell or bone marrow transplantation from matched related donors. A case-control study. Spanish Group of Allo-PBT.

Authors:  C Solano; C Martinez; S Brunet; J F Tomás; A Urbano-Ispizua; J Zuazu; E Ojeda; J Bargay; J M Moraleda; A Bailen; J Sierra; J García-Conde; C Rozman
Journal:  Bone Marrow Transplant       Date:  1998-12       Impact factor: 5.483

2.  Extensive chronic GVHD is associated with donor blood CD34+ cell count after G-CSF mobilization in non-myeloablative allogeneic PBSC transplantation.

Authors:  N Dhédin; T Prébet; R Peffault De Latour; S Katsahian; M Kuentz; N Piard; D Réa; F Norol; J P Jouet; J A Ribeil; R Tabrizi; B Rio; B Lioure; P Tiberghien; J H Bourhis; A Sirvent; P Bordigoni; D Blaise; M Michallet; J P Vernant
Journal:  Bone Marrow Transplant       Date:  2012-05-21       Impact factor: 5.483

3.  Long-term follow up after allogeneic stem cell transplantation in patients with severe aplastic anemia after cyclophosphamide plus antithymocyte globulin conditioning.

Authors:  Johanna Konopacki; Raphaël Porcher; Marie Robin; Sabine Bieri; Jean-Michel Cayuela; Jérôme Larghero; Aliénor Xhaard; Anna Lisa Andreoli; Nathalie Dhedin; Anna Petropoulou; Paula Rodriguez-Otero; Patricia Ribaud; Hélène Moins-Teisserenc; Maryvonnick Carmagnat; Antoine Toubert; Yves Chalandon; Gérard Socie; Régis Peffault de Latour
Journal:  Haematologica       Date:  2011-12-16       Impact factor: 9.941

4.  National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report.

Authors:  Alexandra H Filipovich; Daniel Weisdorf; Steven Pavletic; Gerard Socie; John R Wingard; Stephanie J Lee; Paul Martin; Jason Chien; Donna Przepiorka; Daniel Couriel; Edward W Cowen; Patricia Dinndorf; Ann Farrell; Robert Hartzman; Jean Henslee-Downey; David Jacobsohn; George McDonald; Barbara Mittleman; J Douglas Rizzo; Michael Robinson; Mark Schubert; Kirk Schultz; Howard Shulman; Maria Turner; Georgia Vogelsang; Mary E D Flowers
Journal:  Biol Blood Marrow Transplant       Date:  2005-12       Impact factor: 5.742

Review 5.  Chronic graft-versus-host disease: clinical manifestation and therapy.

Authors:  V Ratanatharathorn; L Ayash; H M Lazarus; J Fu; J P Uberti
Journal:  Bone Marrow Transplant       Date:  2001-07       Impact factor: 5.483

6.  Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation.

Authors:  K Atkinson; M M Horowitz; R P Gale; D W van Bekkum; E Gluckman; R A Good; N Jacobsen; H J Kolb; A A Rimm; O Ringdén
Journal:  Blood       Date:  1990-06-15       Impact factor: 22.113

Review 7.  Chronic graft versus host disease.

Authors:  Meghan A Higman; Georgia B Vogelsang
Journal:  Br J Haematol       Date:  2004-05       Impact factor: 6.998

8.  Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse.

Authors:  Stephanie J Lee; John P Klein; A John Barrett; Olle Ringden; Joseph H Antin; Jean-Yves Cahn; Matthew H Carabasi; Robert Peter Gale; Sergio Giralt; Gregory A Hale; Osman Ilhan; Philip L McCarthy; Gerard Socie; Leo F Verdonck; Daniel J Weisdorf; Mary M Horowitz
Journal:  Blood       Date:  2002-07-15       Impact factor: 22.113

9.  Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients.

Authors:  H M Shulman; K M Sullivan; P L Weiden; G B McDonald; G E Striker; G E Sale; R Hackman; M S Tsoi; R Storb; E D Thomas
Journal:  Am J Med       Date:  1980-08       Impact factor: 4.965

10.  Incidence and Pattern of Graft-versus-Host Disease in Patients Undergoing Allogeneic Transplantation after Nonmyeloablative Conditioning with Total Lymphoid Irradiation and Antithymocyte Globulin.

Authors:  Lauren Veltri; Michael Regier; Aaron Cumpston; Sonia Leadmon; William Tse; Michael Craig; Mehdi Hamadani
Journal:  Bone Marrow Res       Date:  2013-04-17
View more
  2 in total

1.  Risk Factors for Graft-Versus-Host Disease After Transplantation of Hematopoietic Stem Cells from Unrelated Donors in the China Marrow Donor Program.

Authors:  Fan Yang; Daopei Lu; Yu Hu; Xiaojun Huang; He Huang; Jing Chen; Depei Wu; Jianmin Wang; Chun Wang; Mingzhe Han; Hu Chen
Journal:  Ann Transplant       Date:  2017-06-27       Impact factor: 1.530

2.  Allogeneic hematopoietic stem cell transplantation for relapsed acute myeloid leukemia in ETO positive with reduced-intensity conditioning.

Authors:  Zhi Guo; Chen Xu; Hu Chen
Journal:  Oncotarget       Date:  2017-11-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.